与斑秃相关的合并症:系统综述和荟萃分析。

IF 8.6 1区 医学 Q1 DERMATOLOGY American Journal of Clinical Dermatology Pub Date : 2023-07-18 DOI:10.1007/s40257-023-00805-4
Sophia Ly, Priya Manjaly, Kanika Kamal, Ali Shields, Bruna Wafae, Najiba Afzal, Lara Drake, Katherine Sanchez, Samantha Gregoire, Guohai Zhou, Carol Mita, Arash Mostaghimi
{"title":"与斑秃相关的合并症:系统综述和荟萃分析。","authors":"Sophia Ly,&nbsp;Priya Manjaly,&nbsp;Kanika Kamal,&nbsp;Ali Shields,&nbsp;Bruna Wafae,&nbsp;Najiba Afzal,&nbsp;Lara Drake,&nbsp;Katherine Sanchez,&nbsp;Samantha Gregoire,&nbsp;Guohai Zhou,&nbsp;Carol Mita,&nbsp;Arash Mostaghimi","doi":"10.1007/s40257-023-00805-4","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><p>Alopecia areata (AA) is a complex autoimmune condition resulting in nonscarring hair loss. In recent years, many studies have provided new evidence on comorbid diseases present in patients with AA. However, some studies have conflicting results, and analyses conducting a comprehensive approach are lacking.</p><h3>Objective</h3><p>The aim of our study was to provide an updated systematic review and meta-analysis of medical comorbidities associated with AA.</p><h3>Methods</h3><p>We searched PubMed, Embase, and Web of Science for case-control, cross-sectional, and cohort studies investigating medical comorbidities in AA published from inception through 1 February 2023.</p><h3>Results</h3><p>We screened 3428 abstracts and titles and reviewed 345 full text articles for eligibility. Ultimately, 102 studies were analyzed, comprising 680,823 patients with AA and 72,011,041 healthy controls. Almost all included studies (100 of 102 studies) were of satisfactory to high quality (Newcastle–Ottawa scale score ≥ 4). Among patients with AA, comorbidities with the highest odds ratios (OR) compared with healthy controls and data available from more than one study included vitamin D deficiency (OR 10.13, 95% CI 4.24–24.20), systemic lupus erythematous (OR 5.53, 95% CI 3.31–9.23), vitiligo (OR 5.30, 95% CI 1.86–15.10), metabolic syndrome (OR 5.03, 95% CI 4.18–6.06), and Hashimoto’s thyroiditis (OR 4.31, 95% CI 2.51–7.40). AA may be a protective factor for certain disorders, for which the AA group had lower odds compared with healthy controls, such as irritable bowel syndrome (OR 0.38, 95% CI 0.14–0.99) and colorectal cancer (OR 0.61, 95% CI 0.42–0.89).</p><h3>Conclusion</h3><p>These findings corroborate and contextualize the risks across comorbidities for patients with AA. Further work should be done to identify the underlying pathophysiology and understand appropriate screening criteria.</p></div>","PeriodicalId":7706,"journal":{"name":"American Journal of Clinical Dermatology","volume":"24 6","pages":"875 - 893"},"PeriodicalIF":8.6000,"publicationDate":"2023-07-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Comorbid Conditions Associated with Alopecia Areata: A Systematic Review and Meta-analysis\",\"authors\":\"Sophia Ly,&nbsp;Priya Manjaly,&nbsp;Kanika Kamal,&nbsp;Ali Shields,&nbsp;Bruna Wafae,&nbsp;Najiba Afzal,&nbsp;Lara Drake,&nbsp;Katherine Sanchez,&nbsp;Samantha Gregoire,&nbsp;Guohai Zhou,&nbsp;Carol Mita,&nbsp;Arash Mostaghimi\",\"doi\":\"10.1007/s40257-023-00805-4\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><h3>Background</h3><p>Alopecia areata (AA) is a complex autoimmune condition resulting in nonscarring hair loss. In recent years, many studies have provided new evidence on comorbid diseases present in patients with AA. However, some studies have conflicting results, and analyses conducting a comprehensive approach are lacking.</p><h3>Objective</h3><p>The aim of our study was to provide an updated systematic review and meta-analysis of medical comorbidities associated with AA.</p><h3>Methods</h3><p>We searched PubMed, Embase, and Web of Science for case-control, cross-sectional, and cohort studies investigating medical comorbidities in AA published from inception through 1 February 2023.</p><h3>Results</h3><p>We screened 3428 abstracts and titles and reviewed 345 full text articles for eligibility. Ultimately, 102 studies were analyzed, comprising 680,823 patients with AA and 72,011,041 healthy controls. Almost all included studies (100 of 102 studies) were of satisfactory to high quality (Newcastle–Ottawa scale score ≥ 4). Among patients with AA, comorbidities with the highest odds ratios (OR) compared with healthy controls and data available from more than one study included vitamin D deficiency (OR 10.13, 95% CI 4.24–24.20), systemic lupus erythematous (OR 5.53, 95% CI 3.31–9.23), vitiligo (OR 5.30, 95% CI 1.86–15.10), metabolic syndrome (OR 5.03, 95% CI 4.18–6.06), and Hashimoto’s thyroiditis (OR 4.31, 95% CI 2.51–7.40). AA may be a protective factor for certain disorders, for which the AA group had lower odds compared with healthy controls, such as irritable bowel syndrome (OR 0.38, 95% CI 0.14–0.99) and colorectal cancer (OR 0.61, 95% CI 0.42–0.89).</p><h3>Conclusion</h3><p>These findings corroborate and contextualize the risks across comorbidities for patients with AA. Further work should be done to identify the underlying pathophysiology and understand appropriate screening criteria.</p></div>\",\"PeriodicalId\":7706,\"journal\":{\"name\":\"American Journal of Clinical Dermatology\",\"volume\":\"24 6\",\"pages\":\"875 - 893\"},\"PeriodicalIF\":8.6000,\"publicationDate\":\"2023-07-18\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"American Journal of Clinical Dermatology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://link.springer.com/article/10.1007/s40257-023-00805-4\",\"RegionNum\":1,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"DERMATOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"American Journal of Clinical Dermatology","FirstCategoryId":"3","ListUrlMain":"https://link.springer.com/article/10.1007/s40257-023-00805-4","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"DERMATOLOGY","Score":null,"Total":0}
引用次数: 0

摘要

背景:斑秃(AA)是一种复杂的自身免疫性疾病,导致非持续性脱发。近年来,许多研究为AA患者存在的共病提供了新的证据。然而,一些研究的结果相互矛盾,缺乏全面的分析方法。目的:我们研究的目的是提供与AA相关的医学合并症的最新系统综述和荟萃分析。方法:我们在PubMed、Embase和Web of Science中搜索病例对照、横断面、,以及从开始到2023年2月1日发表的调查AA医学合并症的队列研究。结果:我们筛选了3428篇摘要和标题,并审查了345篇全文文章的资格。最终,分析了102项研究,包括680823名AA患者和72011041名健康对照。几乎所有纳入的研究(102项研究中的100项)都具有令人满意的高质量(纽卡斯尔-渥太华量表得分≥4)。在AA患者中,与健康对照组和一项以上研究的数据相比,优势比(OR)最高的合并症包括维生素D缺乏症(OR 10.13,95%CI 4.24-24.20)、系统性红斑狼疮(OR 5.53,95%CI3.31-9.23)、白癜风(OR 5.30,95%CI 1.86-15.10)、代谢综合征(OR 5.03,95%CI4.18-6.06),和桥本甲状腺炎(OR 4.31,95%CI 2.51-7.40)。AA可能是某些疾病的保护因素,与健康对照组相比,AA组的发病率较低,如肠易激综合征(OR 0.38,95%CI 0.14-0.99)和结直肠癌癌症(OR 0.61,95%CI 0.42-0.89)。
本文章由计算机程序翻译,如有差异,请以英文原文为准。

摘要图片

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
Comorbid Conditions Associated with Alopecia Areata: A Systematic Review and Meta-analysis

Background

Alopecia areata (AA) is a complex autoimmune condition resulting in nonscarring hair loss. In recent years, many studies have provided new evidence on comorbid diseases present in patients with AA. However, some studies have conflicting results, and analyses conducting a comprehensive approach are lacking.

Objective

The aim of our study was to provide an updated systematic review and meta-analysis of medical comorbidities associated with AA.

Methods

We searched PubMed, Embase, and Web of Science for case-control, cross-sectional, and cohort studies investigating medical comorbidities in AA published from inception through 1 February 2023.

Results

We screened 3428 abstracts and titles and reviewed 345 full text articles for eligibility. Ultimately, 102 studies were analyzed, comprising 680,823 patients with AA and 72,011,041 healthy controls. Almost all included studies (100 of 102 studies) were of satisfactory to high quality (Newcastle–Ottawa scale score ≥ 4). Among patients with AA, comorbidities with the highest odds ratios (OR) compared with healthy controls and data available from more than one study included vitamin D deficiency (OR 10.13, 95% CI 4.24–24.20), systemic lupus erythematous (OR 5.53, 95% CI 3.31–9.23), vitiligo (OR 5.30, 95% CI 1.86–15.10), metabolic syndrome (OR 5.03, 95% CI 4.18–6.06), and Hashimoto’s thyroiditis (OR 4.31, 95% CI 2.51–7.40). AA may be a protective factor for certain disorders, for which the AA group had lower odds compared with healthy controls, such as irritable bowel syndrome (OR 0.38, 95% CI 0.14–0.99) and colorectal cancer (OR 0.61, 95% CI 0.42–0.89).

Conclusion

These findings corroborate and contextualize the risks across comorbidities for patients with AA. Further work should be done to identify the underlying pathophysiology and understand appropriate screening criteria.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
CiteScore
15.20
自引率
2.70%
发文量
84
审稿时长
>12 weeks
期刊介绍: The American Journal of Clinical Dermatology is dedicated to evidence-based therapy and effective patient management in dermatology. It publishes critical review articles and clinically focused original research covering comprehensive aspects of dermatological conditions. The journal enhances visibility and educational value through features like Key Points summaries, plain language summaries, and various digital elements, ensuring accessibility and depth for a diverse readership.
期刊最新文献
Ruxolitinib Cream Monotherapy Improved Symptoms and Quality of Life in Adults and Adolescents with Mild-to-Moderate Atopic Dermatitis: Patient-Reported Outcomes from Two Phase III Studies. Intravenous Immunoglobulin Therapy for Pyoderma Gangrenosum: A Multicenter Retrospective Analysis in 81 Patients. Managing Urticarial Vasculitis: A Clinical Decision-Making Algorithm Based on Expert Consensus. Disseminated Superficial Actinic Porokeratosis: A Systematic Treatment Review. Patient-Reported Hair Loss and Its Impacts as Measured by the Alopecia Areata Patient Priority Outcomes Instrument in Patients Treated with Ritlecitinib: The ALLEGRO Phase 2b/3 Randomized Clinical Trial.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1